Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Achieved a multi-year high in recurring revenue, surpassing $6 million, driven by the U.S. launch of the MAGiC robotic catheter following FDA approval.
Robotic catheter revenue grew nearly 300% sequentially, validating the strategy to transition from legacy third-party catheters to a proprietary high-margin ecosystem. Early clinical feedback indicates the MAGiC catheter significantly improves ablation efficiency and navigation, effectively doubling the perceived value of the robotic system for physicians. The Synchrony digital surgery system received FDA clearance and immediate organic interest, serving as both a robotic cockpit and a standalone solution for non-robotic labs.
GenesisX is designed to remove historical adoption barriers by enabling compatibility with standard X-ray systems from major manufacturers without requiring lab construction. Management attributes the current commercial momentum to the successful execution of a synergistic product ecosystem that reduces barriers to entry while improving the business model. Projecting a $1 million incremental step-up in catheter revenue for each of the next two quarters as manufacturing supply constraints are methodically addressed.
Anticipating cash flow profitability in the first half of 2027, assuming modest capital sales and continued ramp of the recurring revenue stream. Planning a more aggressive commercial launch of GenesisX following formal compatibility declarations with major X-ray manufacturers expected this fall. Advancing a robust R&D pipeline including wireless, mobile robotic systems and first-in-human procedures for Pulsed Field Ablation (PFA) before year-end.
Integrating the Robocath acquisition to develop a multi-specialty ecosystem for remote, automated treatment of stroke and cardiovascular disease. Current sales remain supply-constrained as the company works with contract manufacturer Osypka to increase output and clear the existing order backlog. Gross margins are currently impacted by low manufacturing volumes, with significant expansion opportunities projected for 2027 and 2028 as scale increases.
The transition away from Johnson & Johnson catheters has created temporary pressure on procedure volumes during the customer conversion process. Closed the Robocath acquisition in July 2026, expanding the strategic focus toward neurointerventional and interventional cardiology markets. Nvidia-level potential. 30M+ investors trust Moby to find it first.
Extract — continue reading at the source.
